REGISTRATIONS

BioAsia 2012 will bring together all the people who matter in the industry. For you it means the ideal global platform to hear the industry's best, network to further your business, showcase your expertise and strengths and be a part of shared experiences and knowledge with key stakeholders.

BioAsia Secretariat204, Imperial Apartments,Greenlands Circle, BegumpetHyderabad 500 016Andhra Pradesh, IndiaEmail: info@bioasia.in

Organizers

Enhance Enrich Enable… A better world through Biotechnology.

BIOASIA 2012Optimizing Opportunities

February 9-11, 2012, Hyderabad, India

Vaccines | Contract Research | Investments | IPR

Supporting Organizations

Knowledge Partner

AssociatesBio Partnering: Communication Event Marketing Media

RED OO R#0408,

Mind’s solutions

Don't miss out on this opportunity! Register today.

For registrations and to know about our basic packages

and pricing log on to www.bioasia.in

Providing the ideal launch-pad for bio-business - enabling collaborations, joint ventures and M&As.

Today, BioAsia is well-positioned with a strong presence across 20 Asian countries & some non Asian countries like US, Spain, Germany, UK, France, etc through the Federation of Asian Biotech Associations (FABA) and a strong hold on the Indian biopharma players through the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL).

With an opportune theme of “Optimizing Opportunities”, the ninth edition of BioAsia is all set to make this biotech platform dynamic than ever, given the rapid developments in the industry. It will facilitate meaningful dialogue, knowledge-sharing and networking opportunities amongst the key stakeholders in the best global interests of biotechnology and humanity.

BioAsia 2012 will focus on four key interconnected areas viz. vaccines, contract research, investments and intellectual property rights that will drive synergies amongst key stakeholders and participants. BioAsia 2012 intends to focus on these areas in the context of changing trends, continuous challenges, potential for growth and future development.

A global footprint that works to your advantage

BIOASIA 2012:

Use the forum's edge to sharpen yours

Optimizing Opportunities

4-fold Focus. Many-fold impact

At the turn of the century, Biotechnology has evolved from a science to impacting human life in more ways than one. The industry has witnessed dynamic changes and paradigm shifts with interplay between the West and Asia in terms of capital innovation ratio to boost biobusiness. Asia has evolved from being only an outsourced destination to a veritable hub of biotechnology innovation.

In this growing industry, game-changing strategies and relevant application of the knowledge-intelligence resource pool will drive the process of growth. BioAsia seeks to channelize inputs from the captains of biotech & pharmaceutical companies, venture capitals, policy makers, industry analysts, academicians, universities, R&D hubs and other major stakeholders to evolve an enriched progress in translating the immense promise of the industry into potential outcomes. Initiated by the Government of Andhra Pradesh in 2004 to promote biotechnology in Andhra Pradesh, BioAsia has emerged as a global brand and has been offering the most sought platform for convergence of business leaders, policy makers, investors etc. BioAsia has been extremely successful in bringing together the who’s who of biotech and biopharma across the globe.

With a vision committed to the promise of biotechnology, BioAsia seeks to enhance, enrich and encourage newer innovations, path-breaking discoveries and effective solutions in the healthcare industry by:

Offering a vibrant global platform for key industry stakeholders - biotech & bio-pharma companies, research institutions, investors, service providers, policy makers, regulators and analysts.

Encouraging knowledge and experience sharing amongst academia and research scientists.

By creating a dynamic experience-pool drawing live instances from industry thought-leaders and through panel discussions.

BioAsia is your Asian gateway to explore this immense potential of biotechnology.

What you can expect

VACCINES

Opportunities

Challenges

Registering a steady upward growth, the global vaccine industry is well poised to meet the global health & immunization challenges, with the developing countries like India slowly capturing the market traditionally dominated by North America & Europe. Besides, increased involvement in the new-vaccine delivery systems and biotherapeutics, smaller players are starting to drive the vaccine segment by collaborating with the premier research institutions & academia and channelizing their seed capital for innovative research. This approach has so far yielded high returns either through outsourcing or product development & manufacturing contracting with the big companies. The burgeoning demand in the pediatric vaccine segment and increasing health awareness among the middle class boosts opportunities in this niche segment. Constant encouragement and significant financial support from global organizations on various immunization programs, is expected to act as the springboard to propel the vaccine market to a high growth curve in the next 10 years.

While the market promises drastic growth, challenges do exists in terms of establishing clinical safety and efficacy of new vaccines, regulations becoming stringent & complex, effective demand & limited supply, barriers and effective synergies in costing & pricing, huge gaps in logistic and quality control in cold chain management to mention a few. BioAsia 2012 seeks to address these challenges and work towards collaborative and positive outcomes.

1. Hyderabad is India’s hub for vaccine production

2. 70% vaccines supplied to the UNICEF in 2010-11 was from developing countries, majorly from 5 Indian manufacturers - Serum Institute, Panacea Biotech, Bharat Biotech, Biological E and Shantha Biotech

3. In 2010-11, vaccine sector witnessed a 12% growth with a revenue of USD 550 Mn

4. Domestic market for vaccines is USD 300 Mn

5. Key vaccines in India remain those mentioned in the National Immunization Schedule in India, though there is some developing market for newer vaccines types like Influenza

Facilitate discussions on global trends & opportunities in vaccines & recombinant DNA technology.

Provide a platform for multinational companies envisaging interest and aspiring to make inroads into the Indian/Asian vaccine market.

Attempt to narrow the gap between the demand and supply sides together across one common table.

Enable discussions and recommendations regarding pre-clinical approvals & clinical trial regulations

Facilitate discussions that can translate into progressive commitments.

Enable interactions with and between participating vaccine companies.

Open up avenues for meaningful knowledge sharing on technological assessments.

Facilitate dialogue with NGOs to promote public awareness of Vaccine-Preventable Diseases in B-tier towns and rural areas.

BioAsia 2012 will:

Indian Vaccine Market - Fact file

2 7

CONTRACT RESEARCH ORGANIZATIONS (CROs)

Opportunities

Challenges

It is universally accepted that Contract Research Organizations (CROs) greatly impact drug research and commercialization of various medical products. Today, pharmaceutical companies actively seek CROs to manage various aspects of clinical research. In fact, the smaller CROs are in favor since they offer advantages in terms of responsiveness, in-depth therapeutic expertise, leveraging electronic data capture and thereby saving on expensive staff-intensive data management capability.India and China is fast emerging as the hunting ground for major, global pharmaceutical players for several reasons: sagging top lines of pharmaceutical majors, lack of research funds, research hubs running out of patents and the post-recession panic of cost reduction by cutting down on field staff and outsourcing core functions. Indian CROs offer advantages over their global counterparts - skill, readily available manpower, cost advantages, large and diverse patient population, easy availability of volunteers for clinical trials and speedy deliveries. India also has an edge over China in Data Management resulting in speedier deliveries.

The fast emerging Indian CRO segment also has its fair share of grey areas in terms of lack of governmental push, tax incentives, infrastructure support, etc. as against the case in China, IP regulations, confidentiality issues, lack of uniform national monitory systems, complex regulatory procedures to name a few. Added to these are relatively friendly regulations in the emerging of markets of Thailand & Vietnam. On a large level there is a need in the entire CRO segment itself to raise the quality bar to achieve a continual zero-accuracy in data management and better process outflows and the need to open up better communication channels with big pharmaceutical companies.

INVESTMENTS

Opportunities

Challenges

The link between venture capital funding and biotechnological innovations is crucial and just as difficult to forge. While most VCs prefer to wait and watch till the research takes a concrete shape before investing, a lot of R&D initiatives require capital right from day one. The good news is that, finally with the healthcare and biotech sectors gathering force, the bottlenecks seem to be dissolving, albeit slowly. Many developing countries involved in key research activities have initiated collaborations with multinational companies, entrepreneurs and other VC groups who are open-minded and future-oriented enough to be a part of the investment environment in biotechnology. The possibilities in and for India seem even brighter and for a variety of reasons such as cost-effectiveness, diverse Indian patient population inspiring purposeful research, encouraging initiatives by the government in biotechnology R&D, availability of government soft loans and grant-in-aid for private players even in high-risk areas, support of VC bodies (Indian Private Equity & VCs Association, New Delhi, GITA etc) and a native coterie of well-meaning entrepreneurs who can bring value through skills, domain expertise and strategic planning.

BioAsia 2012 intends to address the unique challenges facing investments such as gaps in Industry-Academia collaborations leading to low investments in R&D, creating awareness of the intrinsic nature of biotech research which involves more gestation time-to-scale vis-a-vis other industries and the need for venture capitalists to hand-hold research initiatives at

the earliest stages. BioAsia 2012 will also enable biotech companies understand the needs and requirements for a VC for funding a venture with their viewpoint on information requirements, clarity in business plans and return on investments made.

Facilitate dialogue between participant VCs, business leaders, entrepreneurs and the academia.

Enable possibilities for JVs between pharmaceutical companies to fund research initiatives.

Create an effective discussion forum to address the unique challenges in the global and Indian VC environment.

Enable an effective dialogue between policy makers, pharmaceutical companies and industry research companies to explore possibilities of effective collaboration.

Conduct a series of sessions with presentations by research professionals, entrepreneurs, CEOs etc. on the role of VC funding in the biotechnology.

BioAsia 2012 will:

1. Indian CRAMS market reached USD 1700 Mn in 2008-09, contract manufacturing contributing the major chunk

2. Contract research services valued around USD 600 Mn in 2008-09, contributing to 35% of the total Indian CRAMS market

3. Indian CROs benefit from the availability of skilled manpower in India with experience in development of various molecules

4. With rising cost of research, innovator companies can see cost effective solutions by engaging with Indian CROs for specified research activities

5. Indian CROs also offer time benefits to their innovator counterparts by virtue of their working structure

Indian Contract Research - Fact file

Offer a platform to the Global CRO community to meet/discuss possible collaborations, acquisitions, mergers etc.

Provide participants an exposure to global regulations for conducting Clinical Trials

Facilitate interactions with big and mid-sized Pharmaceutical companies from India & abroad looking for outsourcing services

Debate on the bottlenecks and challenges for CROs and recommend policy decisions

Organize a CRO tour of companies in Genome Valley, the emerging CRO hub of India consisting of a rich blend of local and multinational CROs, for interested participants.

BioAsia 2012 will:

6 3

INTELLECTUAL PROPERTY RIGHTS

Opportunities

Challenges

Intellectual Property Rights in relation to biotechnology is more than crucial to encourage continued investment in R&D, to strengthen the innovative base, to protect regulatory data and confidential information and much more. Product development partnerships hinge on complex IPR management issues; IPRs are either directly or indirectly linked to research (access to proprietary enabling technologies, development of IPR assets; genomics and bio-informatics, bio-prospecting and access to genetic resources); trade (patenting, commercialization of technology and control of restrictive licenses); technology transfer (technology transactions, technology packaging, remuneration); and traditional knowledge. The role of IPRs will further deepen and widen to accommodate more of Indian scientific research and technology-based business.

However there is a need for flexibility in existing legal frameworks, sensitivity to innovations, products and categories not to mention an overall low-level awareness levels about IPRs in general. BioAsia 2012 intends to address some of these issues including industry understanding and stance on the Section 3(d)of the Indian Patent Act and facilitate meaningful dialogues with key stakeholders resulting in positive outcomes.

BioAsia 2012 will:

Provide exposure to various IPR protection strategies.

Facilitate dialogue between IPR firms, law firms, business entities and academia.

Facilitate exploration of new opportunities for new IPR firms and biotech startups.

Provide opportunity for collaborations and dialogue between IPR firms, Industry stakeholders and academia.

Enable comparative discussions on the IPR regime across various jurisdictions.

Highlight issues related to strengthening of IPR portfolio and IPR Asset Management in organizations.

Business partnering (B2B)

BioAsia features a dedicated B2B-portal, which assists you in your business development and licensing activities with hand - picked companies from the Asian Life Sciences marketplace, in addition to assisting expansion of your professional network. B2B-partnering at BioAsia 2012 will enable you to create your personal 3-day schedule of private one-on-one meetings with your potential counterparts. Envisioned to support participants in their business development activities, a focused range of business support services are being offered free of cost to all registered participants including company presentations, product promotions, licensing opportunities, collaborator search, etc.

BioBazaar International Buyer-Seller Meet

Networking opportunities

Tradeshow

Let your business buzz

Showcase yourself

BioAsia 2012 goes the extra mile to help you leverage maximum mileage for your business offering a dedicated networking time to enable you interact towards fruitful outcomes with your industry peers. We create a vibrant environment with adequate physical infrastructure support in the form of conclaves, biopark tours, luncheons, receptions, gala dinners and awards ceremonies all intended to provide you the perfect networking ambience. Participants will benefit largely from the dynamic, informal atmosphere that encourages purposeful dialogue, interactions and collaborations.

BioAsia 2012 offers you the ideal forum to showcase your strengths, expertise and offerings. With ample display areas and a captive audience involving a dynamic participant portfolio mix, BioAsia offers you an environment to optimize your brand equity and business offerings.

Here is your perfect opportunity to engage, converse, enrich and grow your business!

Biopharmaceuticals today presents burgeoning market opening the doors for biobusiness. BioBazaar, the first of its kind in India is organized by Pharmexcil at BioAsia 2012. A Buyer-Seller Meet, BioBazaar's objective is promoting the interests of the Indian Biopharma and Medical device sectors. BioBazaar is the “one stop” for various biopharma products such as vaccines, monoclonal antibodies, biogenerics, blood products and medical devices. It is your one point access to top notch Indian sellers and potential international buyers. BioBazaar was introduced in BioAsia 2011 which was attended by 31 global delegates across 16 countries and over 100 Indian delegates.

For participation details log on to www.bioasia.in

4 5